It targets only one receptor (GLP-1) compared to tirzepatide dual and retatrutide triple
Small, nutrient-dense, and usually tolerable even with reduced appetite
Moreover, mice receiving GLP-1 monotherapy displayed significantly lower insulin levels compared with mice that were treated with MK-801 alone
When combined with healthy lifestyle habits, these metabolic improvements create a supportive environment for substantial, sustainable weight loss
How Employers Are Controlling Costs In response, many employers are moving away from openended GLP1 coverage and shifting to more targeted, costcontrolled strategies, such as: Limit plan eligibility
Many patients who plateau on Semaglutide already switch to Tirzepatide successfully